

Index

A

- AAP, *see* Activatable aptamer probe (AAP)
- Acoustic attenuation, 357
- Acoustic imaging, 258
- Acoustic-resolution photoacoustic microscopy, 464
- Activatable aptamer probe (AAP), 81
- Adenovirus detection, 445
- Adipocytes, 309, 310, 315
- A-fetoprotein detection, 430, 434
- Aggregation-induced-emission (AIE), 540, 561
- AIE, *see* Aggregation-induced-emission (AIE)
- Algae, 278, 306, 310
- Alpha-fetoprotein (AFP), 375
 - detection, 430, 434
- Alternating current (AC) magnetic susceptibility, 371
- Alzheimer's disease (AD), 1, 4, 51, 53, 205, 378
- Amide, 23
- Amyloid, 2, 19
- Amyloid β -protein, 436
- Analyte, 263
- Anisotropic field, 385
- Antibiotics, 46
- Antibody, 12, 15, 21, 25–27, 31
- Antibody-antigen interaction, 389
- Anticarcinoembryonic antigen, 407
- Antigen, 2, 12, 21, 26, 36, 38
 - detection, 431
- Applications
 - Alzheimer's disease, 300, 310
 - amyotrophic lateral sclerosis, 311
 - apoptosis, 286, 296, 304
 - atherosclerosis, 300, 315
 - bacterial infection, 280, 301, 302, 306, 314
 - biochar, formation of, 313
 - biofilms, 313
 - cancer, 296–301, 303
 - cell cycle, 297, 315
 - chromosome dynamics, 312
 - contaminant detection in food, 308
 - Crohn's disease, 315
 - diabetes, 300
 - drug composition, 303, 309
 - drug treatments, 278, 301–303, 305, 310–312
 - early embryo development, 306, 309
 - fruits, composition of, 306, 308, 311
 - hypertension, 300
 - malaria, 301, 302, 315
 - mineralisation, 304
 - nanoparticle uptake, 303, 310
 - non-alcoholic fatty liver disease, 315
 - parasite infection, 301, 308
 - plants, composition of, 305
 - pollen grains, composition of, 305
 - stroke, 300
 - substitutions food detection, 309
 - sweating, monitoring of, 310
 - vegetables, composition of, 317
- Aptamers
 - activatable aptamer probe, 81
 - DNA nanostructures, 81
 - hybridization chain reaction, 82
 - target imaging, 81
- Aptasensor, 443–444, 450–451
- Arc-array, 467
- Atomic force microscopy, 314
- ATR-FTIR spectroscopy
 - benchtop, portable and handheld instruments, 175
 - biofluids, 167
 - cells, 167

- ATR-FTIR spectroscopy (*cont.*)
diagnostic/exploratory, 176
focal plane array detectors, 176
generate maps, 176
imaging mode, 176
linear array, 176
point spectra, 174, 176
post-analytical phase, 168
pre-analytical phase, 168
robust biomarkers, 198
single/multiple reflection, 176
spectral acquisition, 174–175
spectral and spatial resolution, 176
spectral preprocessing, 174–175
surface enhanced IR absorption, 175
tissues, 167
- Average magnetic moment, 391
Average separation, 391
Avian influenza virus detection, 445
- B**
- Bacteria, 214, 222, 227, 229, 234, 238, 240, 244, 247
Bacteriophage MS2, 445
Basophils, 449
Benzothiadiazole (BT), 566
Beta thalassemia major (β -TM), 201
Binding affinities, 230, 234, 246
Biocompatibility, 4, 6, 31, 32, 76, 198, 359, 518, 522
Bioconjugation, 254, 371
Biodegradation, 401
Biodetection and multimodal bioimaging
luminescent resonance energy transfer, 251
positron emission tomography, 251
semiconductor quantum dots, 250
upconversion nanocrystals, 250
Biodistribution and micro-SPECT imaging, 513
Biofluids, 164, 166, 170–173
anticoagulants, 168, 172
blood samples, 170, 172
dried samples, 172
endometrial/ovarian cancer, 204
fixative solutions, 172
freeze-thaw cycles, 171, 172
IR reflective low-E, 173
penetration depth, 173, 177
plasma/serum, 203
thickness, 173, 174, 183
Biological materials, 164
Bioluminescence emission spectra, 547
Bioluminescence imaging, 551, 554
Bioluminescence resonance energy transfer (BRET), 540, 544
Biomarkers, 4–6, 9, 11, 12, 20–30, 33, 35, 36, 54
Biomedical imaging agents, *see* Contrast agents
Biomedical research, 214, 216, 246, 247
Bioprobe, 371
Biosensing technique, 216, 242
Biosensor, 214, 215, 220, 227, 229, 234, 238, 239, 242, 243, 245–247
reliability, 269
Biospectroscopy
clinical implementation, 164, 166, 168
diseases, 163–164, 167, 168
Bisthiethylene derivatives (BTE), 555
Blocking temperature, 384–393
BODIPY, *see* Boron dipyrin (BODIPY)
BODIPYs, *see* Boron dipyrromethenes (BODIPYs)
Boltzmann constant, 129
Bone cells, 304
Boron dipyrin (BODIPY), 569
Boron dipyrromethenes (BODIPYs), 75
Bottom-up substrates, 10
Bovine serum albumin (BSA), 2, 10, 16, 35, 562
Brain tissue, 200
Breast imaging system, 469
Brillouin imaging, 313
BSA, *see* Bovine serum albumin (BSA)
BT, *see* Benzothiadiazole (BT)
BTE, *see* Bisthiethylene derivatives (BTE)
BTTPF dots, *see* Poly (BTTPF) dots
Bubble dual-modal composites, 355–357
- C**
- C7-FA, *see* Heptylamine modified folate (C7-FA)
Cancer, 2, 4, 24–29, 31, 215, 229, 231–235, 237, 241, 245, 246
Cancer therapy, 516
Canine distemper virus, 445
Carbohydrates, detection of, 305, 306
Carbon dots
high photostability, 90
pharmacokinetics, 92
photodynamic efficacy, 90
top-down approaches, 89–90
Carbon nanotubes (CNTs), 349
3D reconstruction, 93
auto-fluorescence, 92
NIR II fluorescent imaging, 92
principal component analysis, 93

- Cardiac biomarkers detection, 434
Cardiomyocytes, 296, 312
Cardiovascular disease, 2, 20–21
Carotenoids, 284, 296, 298, 306, 308
CARS, *see* Coherent anti-Stokes Raman scattering (CARS)
- Cells
 activation, 203
 adipocytes, 309, 310, 315
 bone cells, 304
 cardiomyocytes, 296, 312
 chondrocytes, 317
 dendritic cells, 297
 detection, 445–449
 endothelial cells, 296, 300, 301
 erythrocytes, 297, 301, 302, 314, 315
 fibroblasts, 303
 glial cells, 296
 HeLa cells, 303
 hepatocytes, 296, 310
 keratinocytes, 311
 leukocytes, 295, 296
 lymphocytes, 296, 297
 macrophages, 301
 melanocytes, 310
 microorganisms, 296
 muscle cells, 306, 317
 myeloblasts, 298
 ovary, 296
 plant cells, 305, 306
 promyelocytes, 298
 sperm, 296, 315
 stem cells, 296, 304, 311, 312, 315
 tumour cells, 296
 yeast, 295
- Cellulose, detection of, 283, 305, 309, 311
Cerebrospinal fluid, 378
Cetuximab, 451
Chemical exchange saturation transfer (CEST), 350
Chiral sensing, 241
Chloramphenicol, 379
Chondrocytes, 317
Chronic obstructive pulmonary disorder, 205
¹³C-labeled metabolites, 145, 158
Clearance issue, 268
Close-packed structure, 391
CLSM, *see* Confocal laser scanning microscopy (CLSM)
Cocaine, 204, 450–451
Coherent anti-Stokes Raman scattering (CARS), 287
Colloid, 253
Colored microbubble, 477–481
Confocal laser scanning microscopy (CLSM), 70–71, 569
Confocal micro-Raman photons, 7
Conjugated bilirubin, 371
Conjugated polyelectrolytes (CPEs), 84
Conjugated polymer (CP), 84
Conjugated polymer dots, 539, 540, 544, 554, 571
Connexin 43, 451–452
Continuous flow platforms, 11
Continuous glucose monitoring, 23
Contrast agents, 128, 149, 153, 157
Contrast-enhancing mechanism, 343–344, 349–350
Coregistered SSB image, 407–408
Core/satellite nanotheranostic (CSNT), 48
Core/shell nanoparticle, 391
Core size, 389
Correlation length, 385
CP, *see* Conjugated polymer (CP)
CPEs, *see* Conjugated polyelectrolytes (CPEs)
C-reactive protein (CRP), conjugation, 387
Creatine kinase, 2, 20
Critical temperature, 391
CSNT, *see* Core/satellite nanotheranostic (CSNT)
Cyanine dye, 74
Cyanobacteria, 303
Cystography, 500
Cytochrome, detection of, 295, 296, 304
Cytology
 cervical cytology, 169, 170
 cervical dysplasia, 201
 fixed cells, 169
 fixed fibroblast cells, 202
 gold nanoparticles, 201
 liquid-based cytology, 202
 live cells, 174
 sputum cells, 201
- D**
Data pre-processing, 289
 background removal, 290
 baseline correction, 291
 edge effects, 291
 normalisation, 291, 292
 smoothing, 290
Data visualisation, 292
Dendrimer-based nanoplatfoms, 511–512
 preparation of, 512
 SPECT/CT imaging, 516–520

- Dendrimer-based nanoplatfoms (*cont.*)
 SPECT imaging, 512–516
 SPECT/MR imaging, 520–521
 SPECT/optical imaging, 521–523
 theranostics, 523–527
- Dendrimer(s)
 characteristics, 512
 components, 511
 definition, 511
 nanoplatfoms (*see* Dendrimer-based nanoplatfoms)
- Dendritic cells, 297
- Dewar thickness, 369
- Dextran-coated Fe₃O₄, 387
- Diabetes mellitus, 4, 21, 54
- Dichroic mirror, 7, 8
- Diclofenac, 450
- Diethylenetriaminepentaacetic acid (DTPA), 513–516
- Digital holographic microscopy, 314
- Dipolar interaction, 389
- Dipole interaction energy, 389
- Disease diagnostics, 68, 213–216, 227, 242
- Disordered spin surface, 390
- DNAs, 214, 224, 226, 227, 229, 241, 440, 442–443
 nanostructures, 81
- DNP, *see* Dynamic nuclear polarization (DNP)
- Domain area, 389
- DOTA chelation, 520
- Doxorubicin (DOX), 48, 544, 548
- Droplet based platfoms, 11
- Drug, 214, 227, 234, 238–242, 245, 247
 delivery system, 523
 screening, 234, 240, 247
- Drug detection
 Basophils, 449
 cetuximab, 451
 cocaine, 450–451
 connexin 43, 451–452
 Diclofenac, 450
 erythromycin, 452
 methotrexate, 450
 metoprolol, 449
 molecular imprinting, 434, 449–453
 naproxen, 450
 paracetamol, 450
 theophylline, 450–451
- DTPA, *see* Diethylenetriaminepentaacetic acid (DTPA)
- Dual gas manifold, 252
- Dual-imaging, 401
- Dual mode imaging, 355, 520, 521
- Dynamic laser scattering (DLS), 555
- Dynamic nuclear polarization (DNP), 128–134, 136–138, 141, 143, 145–148, 151, 152, 154, 157
- E**
- Early-stage tumors, diagnosis of, 69
- Echogenic liposomes, 347–348
- Electric field standing wave (EFSW), 173
- Electron spin resonance (ESR), 133, 137, 142
- ELISA, 2, 12, 21, 24
- Endogenous chromophores, 460, 477
- Endogenous contrast agents, 462
- Endothelial cells, 296, 300, 301
- Energy barrier, 384
- Enhanced permeability and retention (EPR), 540, 557–559, 561
- Enhancement mechanism, 5, 6, 8
- Enzyme-linked immunosorbent assay (ELISA), 2, 12, 21, 24
- Enzyme(s)
 6-mercaptapurine, 52–53
 Alzheimer's disease, 51
 biomarker, 50
 BSA, 52
 cancer, 50, 51, 53
 SERS-active substrates, 51
 telomerase, 50–52
 thiopurine S-methyltransferase, 50
- Epidermal growth factor receptor, 2, 27, 31
- EPR, *see* Enhanced permeability and retention (EPR)
- Erythrocytes, 297, 301, 302, 314, 315
- Erythromycin, 452
- Escherichia coli*, 447–448
- ESR, *see* Electron spin resonance (ESR)
- Exogenous contrast agents, 460, 477
- Exosome detection, 434
- Ex vivo*, 29, 368
- F**
- FA, *see* Folic acid (FA)
- FACS, *see* Fluorescence-activated cell sorting (FACS)
- FAPs, *see* Fluorogen activating proteins (FAPs)
- Farady's law of induction, 412
- Fatty acids, detection of, 298, 309, 310
- Fe₃O₄-antiCRP-CRP cluster, 387
- Fe₃O₄-antiCRP nanoparticle, 387
- Ferritin protein, 417

- Fibroblasts, 303
Figure of merits (FOM), 220, 253, 263
Flavin adenine dinucleotide, 42
FLIM, *see* Fluorescence lifetime imaging microscopy (FLIM)
Fluorescence, 8, 24, 31
 comparative imaging with, 295
 imaging, 68
 labels, 371
Fluorescence-activated cell sorting (FACS), 99
Fluorescence lifetime imaging microscopy (FLIM), 72
Fluorescence resonance energy transfer (FRET), 540, 542, 544, 545, 557
Fluorescent molecule, 512
Fluorescent nanodiamond (FND)
 fluorescence-activated cell sorting, 99
 real-time selective fluorescence imaging, 100
 toxicity assessments, 98
5-Fluorocytosine, 48
Fluorogen activating proteins (FAPs), 80
Fluoroimmunoassay, 392
Fluoroquinolone, 46
FND, *see* Fluorescent nanodiamond (FND)
Folate and RGD Targeting
 bovine serum albumin, 562
 heptylamine modified folate, 560
Folic acid (FA), 513
FOM, *see* Figure of merits (FOM)
Food and Drug Administration (FDA), 352, 359
FRET, *see* Fluorescence resonance energy transfer (FRET)
Full-ring array, 465
Fungi, 280, 306
- G**
Gadolinium (Gd), 512
 contrast agents, 520
 nanoparticles, 350–351
Gamma ray, 257
Gas-containing nanobubble, 344
Gas core nanobubbles, 344–346
Gas-filled microbubbles, 343
Gas-generation
 nanoparticles, 348
 nano-scaled substances, 344
Gastric cancer, 28
Gastrointestinal tract, 498–500
 imaging, 498
GDQs, *see* Graphene quantum dots (GQDs)
Gene delivery system, 523
GFP, *see* Green fluorescent protein (GFP)
Glial cells, 296
Glucose, 2, 21–24
Glycogen-to-phosphate, ratio of, 198
GNPs, *see* Graphene nanoparticles (GNPs)
GO, *see* Graphene oxide (GO)
Gold (Au)
 construction, 512
 nanoparticles, 477, 496
 nanostructures, 462
Graphene, 93
Graphene-based nanomaterials
 graphene quantum dots, 96
 multi-functional nanomaterials, 97
 physiological solubility, 94
 in vivo biodistribution, 96
Graphene nanoparticles (GNPs), 95
Graphene oxide (GO), 93
Graphene quantum dots (GQDs), 93, 96
Green fluorescent protein (GFP), 79
Grueneisen coefficient, 462
Gyromagnetic ratio, 129, 145, 149, 393
- H**
Halbach array, 414
Hand-held imaging probe, 469
HCC, *see* Hepatocellular carcinoma (HCC)
HCR, *see* Hybridization chain reaction (HCR)
Heart tissue, 200
HeLa cells, 303
Heme detection, 284, 296, 297, 300–302
Hemoglobin, 376
 detection, 301, 302
Hemozoin, 33, 34
Hepatitis B, 2, 35
Hepatitis B virus, 433
Hepatocellular carcinoma (HCC), 257, 381
Hepatocytes, 296, 310
Hepcidin-25, 438
Heptylamine modified folate (C7-FA), 560
Heterogeneous biodetection
 antibody, 265
 antigen, 265
 clinical Ebola virus, 267
 complementary DNA, 266
 nanochannels, 266
Hierarchical cluster analysis (HCA), 294, 295
High resolution, 69
HIV/AIDS, 2, 37, 204
Hormone detection
 hepcidin-25, 438
 luteinizing hormone, 438

- Hormone detection (*cont.*)
 pituitary hormones, 438
 testosterone, 438–439
- Human papillomavirus, 2, 27
- Hybridization chain reaction (HCR), 82
- Hydrodynamic diameter, 555
- Hydroxyapatite, detection of, 300, 304
- Hyperpolarization, 128, 130, 131, 133, 136, 140, 142, 145, 146, 149, 151, 154
- Hypoxia
 lifetime-based O₂ sensing, 569
 luminescence imaging, 551
 Pt(II)-porphyrin, 569
 self-assembled FP-Pdots, 571
- Hysteresis curve, 380
- I**
- ¹³¹I, *see* Iodine-131 (¹³¹I)
- IgG detection, 432
- Illicit drugs, 49
- Image contrast, 398
- Imaging agents, 511
- Immunoassays, 5, 12, 35–36, 38, 44, 54
- Immunohistochemistry, 407–410
- Immunomagnetic reduction (IMR), 371–380
- ¹¹¹In, *see* Indium-111 (¹¹¹In)
- Independent component analysis (ICA), 291
- Indium-111 (¹¹¹In), 513, 515
- Inflammatory markers, 347
- Influenza nucleoprotein, 436
- Infrared spectroscopy, 133, 135, 312, 313
- In situ* colloidal Knoevenagel polymerization
 method, 542, 546–547
- Instrumentation, 284
 calibration, 290
 CARS, 287
 excitation wavelength, 284
 hyperspectral CARS, 288
 point *versus* imaging, 284
 Raman, 284
 SRS, 289
- Interaction intensity, 386
- Internalization, 268
- Intestine tissue, 200
- Intracellular model, 264
- Intraperitoneal tumor, 256
- Intravascular ultrasound (IVUS), 347
- In vitro*, 368
- In vivo*, 4, 6, 13, 14, 22, 23, 368
 application, 258
 fluorescence imaging, 554
 tumor targeting, 69
- In vivo* optical imaging
 biodistribution, 551
 confocal laser microscope, 551
 hypoxia luminescence imaging, 551
 lymph node imaging, 550
 tumor imaging, 550
 vasculature imaging, 551
- Iodine-131 (¹³¹I), 523
- Iron oxide, 359, 512
 in microcapsules, 355
- Iron oxide nanoparticles (IONPs), 350–353
- IVUS, *see* Intravascular ultrasound (IVUS)
- J**
- Josephson junction, 369
- K**
- Keratinocytes, 311
- Kidney tissue, 200
- K-means clustering, 294
- L**
- Label-free detection, 220, 227, 229, 231, 232, 234, 235, 238, 241, 242, 245, 247
- Laminin-5, 436
- Langevin function, 380
- Lanthanide-doped upconversion nanocrystals (UCNCs), 278
- Leucomalachite green, 379
- Leukocytes, 295, 296
- Lignin, detection of, 305, 311
- Limit of detection (LOD), 214, 220, 222, 227, 229, 232, 234, 237, 241, 263
- Linear array transducer, 474–475
- Lipids, detection of, 281, 295–298, 300–302, 305, 306, 308–311, 313, 314
- Liposomal ICG, 481
- Liposomal nanoformulation, 481–488
- Liquid state, 172
- Livertissue, 200
- Living cells, morphological details, 69
- Lobe, 407
- Localized surface plasmon coupled
 fluorescence, 392
- Localized surface plasmon resonance (LSPR),
 216, 218, 220, 222, 224, 229, 232, 234,
 241, 245, 247
- Logistic function, 378
- Long circulation time, 573
- Longterm photostability, 556

- Low cytotoxicity, 69–70
Low-field nuclear magnetic resonance, 393–401
Low scattering, 79
Luminescent resonance energy transfer (LRET), 251
Lung tissue, 200
Luteinizing hormone, 438
Lymphatic basins
 3D reconstruction, 555
 bisthiethylene derivatives, 555
 lymphatic networks, 554
 mass extinction, 555
 nanococktails, 555
 tail-vein injection, 554
Lymphatic networks, 20
Lymph-node imaging, 16
Lymphocytes, 296, 297
Lysozyme detection, 435–436
- M**
- Macrophages, 301, 417
Maghemite, 352
Magnetic anisotropy constant, 385
Magnetic disorder, 390
Magnetic domain
 boundaries, 390
 region, 389
 size, 389
Magnetic force microscopy, 389
Magnetic nanoparticles (MNPs), 368
Magnetic resonance imaging (MRI), 393–401
 acoustically induced rotary saturation, 353
 amine, 134, 135, 140, 141
 amorphous silicon, 138, 141, 142, 147, 151, 157
 animal, 132, 137, 148
 catheter tracking, 154–156
 contrast, 338
 contrast-enhancing mechanism, 349–350
 decay, 130–132, 136, 144, 148, 152
 DNP, 128–134, 136–138, 141, 143, 145–148, 151, 152, 154, 157
 echo time, 338
 ferumoxytol, 353
 gadolinium-based nanoparticles, 350–351
 gradients, 338
 hyperpolarization, 128, 130, 131, 133, 136, 140, 142, 145, 146, 149, 151, 154
 imaging sequences, 136, 149
 iron oxide-based nanoparticles, 351–353
 magnetization vector, 336
 manganese-based nanoparticles, 351
 mobility, 151–154, 157
 nanoparticle research, 354–355
 paramagnet, 137, 144, 147, 149
 phantom, 140, 148, 154–156
 polarization, 128–131, 133, 137–140, 144–146, 148, 149, 152, 157, 158
 proton density, 338
 pulse sequence, 338
 selective excitation, 353
 silicon particles, 133–135
 solid-state DNP device, 131–132
 spin–lattice relaxation, 338, 349
 spin–spin relaxation, 338, 350
 theranostic agents, 128, 157
 transmission antennas, 336
Magnetic resonance signal, 128
Magnetite, 352
Magnetization, 256
Magneto-motive ultrasound (MMUS), 357
Malaria, 32, 34, 54
Manganese (Mn), 520
Mass extinction, 21
Mass spectrometry, 304, 313–314
MB, *see* Microbubbles (MB)
MCF-7 cells, 203
Measurement design, 6
Measurement time, 385
Medical polymers, 198
MEH-PPV, *see* Poly[2-methoxy-5-(2-ethylhexyloxy)-1,4-phenylenevinylene] (MEH-PPV)
Melanin nanoparticles, 494
Melanocytes, 310
Melanoidin, 493
MEMS mirror, 463
6-Mercaptopurine, 52–53
Mesenchymal stem cells, 449
Methotrexate, 45, 450
Methylene blue, 462
 microbubble, 478
Metoprolol, 449
Micelle encapsulated nanoparticle, 486
Microbubbles (MB)
 colored, 477–481
 gas-filled, 343
Microfluidics, 11, 35
Micro/nanofluidics, 214, 215, 227, 242
Microscope, 407
Miniemulsion method, 542
 double emulsion method, 545
 fluorescence quenching, 545
 fluorescent-magnetic nanoparticles, 545
 single emulsion, 544

- Molecular imprinting, 434, 450–452
Molecular sentinel, 2, 26
Morphological details, 69
Moulds, 308
MRI, *see* Magnetic resonance imaging (MRI)
Multicellular organisms
 algae, 278, 306, 310
 cyanobacteria, 303
 fungi, 280, 306
 moulds, 308
 nematodes, 278, 303, 308, 309, 313
 sea squirt, 306
Multifunctional nanoparticles, 512
Multimodal imaging
 atomic force microscopy, 314
 Brillouin imaging, 313
 digital holographic microscopy, 314
 infrared spectroscopy, 312, 313
 mass spectrometry, 313
 second harmonic generation, 315, 317
 two photon emission fluorescence, 315–317
Multimodality image-guided therapy, 573
Multiplex detection, 21, 27, 28
Multivariate curve resolution (MCR), 294
Muscle cells, 306, 317
Mycobacterium tuberculosis, 3, 20, 42
Myelin, detection of, 310, 311
Myeloblasts, 298
Myocardial infarction, 3, 54
Myoglobin, 20
- N**
Nanobubble, 477–481
Nanococktails (NC), 555
NanoDRONE, *see* SPN-based NIR nanoprobe (NanoDRONE)
Nanomaterials, 198
Nanoparticles (NPs), 83
 active targeting, 335
 bubble dual-modal composites, 355–357
 carbon dots, 89–92
 carbon nanotubes, 92–93
 contrast-enhancing mechanism, 343–344, 349–350
 definition, 333
 dose, 359
 echogenic liposomes, 347–348
 fluorescent nanodiamond, 98–100
 gadolinium-based, 350–351
 gas core nanobubbles, 344–346
 gas-generating, 348
 graphene-based nanomaterials, 93–97
 imaging, 334
 iron oxide nanoparticles, 351–353
 magnetic resonance imaging, 336–339
 metabolism, 257
 multidisciplinary knowledge, 359
 multimodal solid, 357
 nanodroplets, 346–347
 noble metal nanoclusters, 105–107
 nono-scaled compounds, 353–355
 passive tumor accumulation, 335
 pathology, 334
 polymer nanoparticles, 83–85
 quantum dots, 85–89
 silica nanoparticles, 107–109
 solid nanoparticles, 348–349
 tunable imaging parameters, 335
 ultrasonic imaging, 339–343
 upconversion nanoparticles, 100–104
 US-MRI studies, 358
 volume fraction, 386
Nanoplatfoms, with dendrimer,
 see Dendrimer-based nanoplatfoms
Nano precipitation method, 541
 exciton diffusion, 542
 MEH PPV (*see* Poly[2-methoxy-5-(2-ethylhexyloxy)-1,4-phenylenevinylene] (MEH-PPV))
 poly(9,9-dioctylfluorene-co-benzothiadiazole) polymer dots, 542, 544
 Stokes shift, 543
Nanoscale biosensor, 214–216, 218, 227, 242
Nano-scaled compounds, 353–355
Naproxen, 450
Narrow detection range, 392
NC, *see* Nanococktails (NC)
NCs, *see* Noble metal nanoclusters (NCs)
Nearest neighbors, 391
Near-infrared (NIR), 539, 541, 544, 556, 560, 566, 568
Near-infrared (NIR)-emitting polymer dots, 539, 573
Near-infrared (NIR) fluorescence imaging, 67
 conjugated polymer dots, 539, 540, 544, 554, 571
 EPR effect, 557–559, 561
 folate and RGD targeting, 560–564
 hypoxia, 569–571
 lymphatic basins, 554–555
 miniemulsion method, 542, 544–546

- nano precipitation method, 541–544
 - reactive oxygen and nitrogen species, 571–573
 - in situ* colloidal Knoevenagel method, 542, 546–547
 - tumor tracking, 564–566
 - tumor vasculature, 555–557
 - UV-absorption and fluorescence spectra, 547–550, 552
 - in vivo* optical imaging system, 550–554
 - Needle biopsy, 405
 - Néel-Arrhenius equation, 384
 - Neisseria meningitidis*, 440
 - Nematodes, 278, 303, 308, 309, 313
 - Neurodegenerative diseases
 - Alzheimer's disease, 13
 - amyloid, 14
 - antibody, 15
 - antigen, 12
 - biomarkers, 15, 17, 18
 - ELISA, 14, 18
 - fluorescence, 18–20
 - immunoassays, 13, 14, 16, 18
 - multiplex, 16, 17
 - plasmon, 14
 - sandwich assay, 15, 16
 - SERS active substrates, 13
 - standard addition, 13
 - tau, 14
 - N-GQDs, *see* Nitrogen-doped graphene quantum dots (N-GQDs)
 - NIR, *see* Near-infrared (NIR)
 - NIR dyes
 - biocompatibility, 76
 - boron dipyrromethenes, 75
 - contrast agents, 74
 - cyanine dye, 74
 - fluorochromes, 73
 - photodynamic therapy, 75
 - phthalocyanines, 76
 - porphyrins, 76
 - squaraine dyes, 74
 - xanthenes dyes, 76
 - NIR-II imaging, 557
 - Nitrogen-doped graphene quantum dots (N-GQDs), 96
 - Noble metal nanoclusters (NCs)
 - background noise, 106
 - biomacromolecules, 105
 - glutathione, 105
 - imaging-guided surgery and therapy, 107
 - renal clearance, 106
 - Noninvasive examination, 401
 - Nuclear magnetic resonance, 393–401
 - Nucleation, 253
 - Nucleic acid detection, 284, 296, 297, 300–302, 311, 314, 315
 - aptasensor, 443–444, 450–451
 - DNA, 440, 442–443
 - Neisseria meningitidis*, 440
 - thrombin-binding aptamer., 440
- O**
- Optical absorption coefficient, 462
 - Optical imaging, 69, 460
 - Optical near-field, 216, 224, 243, 245
 - Optical resolution photoacoustic microscopy, 465
 - Optofluidics, 214, 243
 - Organelles
 - chloroplasts, 310
 - endoplasmic reticulum, 297, 311, 315
 - mitochondria, 295, 296
 - nucleus, 295–297, 299, 301–303, 311
 - phagosome, 301
 - Organic dyes, 477
 - Organic fluorophores, 72
 - aptamers, 81–82
 - fluorescent proteins, 78–81
 - NIR dyes, 73–78
 - transition metal complexes, 78
 - Organic nanoformulated naphthalocyanine, 492
 - Organic nanostructures, 477
 - Organic polymeric nanostructures, 488–495
 - Orthotopic rat model, 257
 - Ovary, 296
- P**
- PAI, *see* Photoacoustic imaging (PAI)
 - PAMAM, *see* Polyamidoamine (PAMAM)
 - Paracetamol, 450
 - Particle diameter, 391
 - Passive tumor accumulation, 335
 - Pathogen, 214, 227, 229, 238–240, 242, 245, 247
 - PCA, *see* Principal component analysis (PCA)
 - PDT, *see* Photodynamic therapy (PDT)
 - Pectin, detection of, 306, 311
 - PEG, *see* Polyethylene glycol (PEG)
 - PEI, *see* Polyethyleneimine (PEI)
 - Peptides, 268
 - Perfluorocarbon (PFC) nanobubble, 481

- PFBT polymer dots, *see* Poly(9,9-dioctylfluorene-co-benzothiadiazole) (PFBT) polymer dots
- PFTTQ, 490
- PFVBT, *see* Poly[9,9-bis(60-(N,N-dimethylamino)hexyl)fluorenyldivinylenalt-4,7-(2,1,3,-benzothiadiazole)] (PFVBT)
- Phantom, 414
- Phemelanin, detection of, 310
- Phosphatebuffered saline, 381
- Phospholipids, detection of, 296, 298
- Photoacoustic computed tomography (PACT), 464–472
- Photoacoustic cystography, 500–502
- Photoacoustic effect, 461
- Photoacoustic imaging (PAI), 250, 460–461
- Photoacoustic microscopy (PAM), 463–464
- Photodamage, 263
- Photodynamic therapy (PDT), 12, 496
- Photoelectrochemical immunoassay, 392
- Photon upconversion nanomaterial, 250
- Photothermal effects, 218, 219, 242
- Photothermal therapy, 496, 498
- Phthalocyanine, 13, 14, 569
- Piezoelectric transducer, 258
- Pituitary hormones, 438
- Plant cells, 305, 306
- Plasma protein A2, 436
- Plasmodfluidics
 - diagnostics, 213–216, 227, 242
 - DNAs and RNAs, 214, 224, 226, 227, 229, 241
 - limit of detection, 214, 220, 222, 227, 229, 232, 234, 237, 241
 - localized surface plasmon resonance, 216, 218, 220, 222, 224, 229, 232, 234, 241, 245, 247
 - photothermal effects, 218–219, 242
 - plasmonic sensor, 231
 - point-of-care, 214, 215, 227, 229, 240, 242
 - surface plasmons, 215, 218, 224
 - thermoplasmonic, 224, 228, 229, 240
- Plasmon, 5, 8, 20
- Plasmon-enhanced thermophoresis, 222, 223
- Plasmonics, 214, 215, 241
 - sensor, 231
 - substrates, 8, 10, 11, 20
 - tweezers, 214, 216, 224, 241
- Pneumonia, 38
- Point-of-care (POC), 38, 214, 215, 227, 229, 240, 242
- Poly[2-methoxy-5-(2-ethylhexyloxy)-1,4-phenylenevinylene] (MEH-PPV), 542–543
- Poly[9,9-bis(60-(N,N-dimethylamino)hexyl)fluorenyldivinylenalt-4,7-(2,1,3,-benzothiadiazole)] (PFVBT), 545
- Poly (BTTPF) dots, 544, 548, 557
- Poly(9,9-dioctylfluorene-co-benzothiadiazole) (PFBT) polymer dots, 542, 544
- Polyamidoamine (PAMAM), 513
- Polycrystalline silicon, 130, 137, 138, 147, 151
- Polyethylene glycol (PEG), 134, 140, 513, 518, 523, 525
- Polyethyleneimine (PEI), 516
- Polymerase chain reaction, 3, 21, 24
- Polymer dots
 - PD-1 polymer dots, 547, 554, 556, 564
 - PD-2 polymer dots, 550, 554
 - PD-3 polymer dots, 551, 554, 564
 - PD-4 polymer dots, 560
 - PD-5 polymer dots, 560
- Polymer nanoparticles, 83
 - conjugated polyelectrolytes, 84
 - conjugated polymers, 84
 - micellar nanocarriers, 85
 - polymer dots, 84
 - quantum yields, 84
- Polypyrrole nanoparticle, 491
- Polysaccharides, 305
- Porphyrin-phospholipid-coated upconversion, 484
- Porphyryns, 12, 13
- Porphysome, 483
- Porshe microbubble, 479–480
- Portable healthcare device, 214, 215, 227, 240, 241
- Postinjection, 411
- Preinjection, 411
- Pre-polarization field, 395
- Principal component analysis (PCA), 30, 292–294, 311, 312, 314
- Probe clearance, 80
- Procalcitonin, 436–438
- Programmable platform, 475
- Promyelocytes, 298
- Proof-of-principle, spectroscopic studies, 198
- Propranolol, 47
- Protein, 214, 224, 226, 231–235, 237
- Protein detection, 280, 282, 295–298, 301–305, 308, 311–315
 - amyloid b-protein, 436
 - antigen detection, 431

cardiac biomarkers detection, 434
exosome detection, 434
hepatitis B virus, 433
IgG detection, 432
influenza nucleoprotein, 436
laminin-5, 436
lysozyme detection, 435–436
plasma protein A2, 436
procalcitonin, 436–438
rheumatoid arthritis, 433, 435
Protein imprinting, 434, 436, 438
Protein plaques, 300
Pseudomonas aeruginosa, 39

Q

Quantum dots
 deep tissue penetration, 88–89
 low cytotoxicity, 87
 multi-mode bioimaging, 88
 multiple color emission, 87
 noninvasive imaging, 87
 tumorous sites, 87
Quinoxaline, 566

R

Radical, 130, 145
Radioactive tracer, 257
Radiolabeling, 525
Radiotherapy, 525
Ramachandran angles, 19
Random anisotropy model, 385
Reactive oxygen and nitrogen species (RONS)
 reticuloendothelial system, 573
 SPN-based NIR nanoprobe, 571
Reactive oxygen intermediate (ROI), 263
Reduced graphene oxide (rGO), 93
Relaxation time
Renal failure, 204
RES, *see* Reticuloendothelial system (RES)
Reticuloendothelial system (RES), 573
rGO, *see* Reduced graphene oxide (rGO)
Rheumatoid arthritis, 205, 433, 435
RNAs, 227, 229, 231
Robust biomarkers, 198
ROI, *see* Reactive oxygen intermediate (ROI)
RONS, *see* Reactive oxygen and nitrogen species (RONS)
Ruderman-Kittel-Kasuya-Yosida-like coupling, 391

S

Salmonella, 448
Sample considerations
 2D and 3D samples, 281
 colour, 280
 labels, 279, 280
 oversampling and undersampling, 286
 sample number, 283
 targetting regions of interest, 287
Sample preparation, 280
 fixation, 281
 imaging media, 283
 substrate coating, 282
 substrates, 282
Sandwich assay, 26, 31
SBR, *see* Signal-to-background ratio (SBR)
Scanning SQUID biosusceptometry, 401–411
Sea squirt, 306
Second harmonic generation, 315, 317
Second near-infrared window, 556
Self-induced back-action (SIBA), 216, 218, 227
Semiconducting p-conjugating polymers, 488–489
Semiconducting polymer nanoparticles, 566, 569
Sensors
 definition, 426
 SPR sensors (*see* Surface plasmon resonance (SPR) sensors)
Sentinel lymph node (SLN), 516
SERS, *see* Surface-enhanced Raman spectroscopy (SERS)
Serum, 381
Severity, 198
Shell thickness, 389
²⁹Si, 128–131, 133–158
Signal-to-background ratio (SBR), 69
Signal-to-noise ratio, 556
Silane, 262
Silica nanoparticles (SiNPs)
 core/satellite nanotheranostic, 108
 downconversion nanoparticles, 109
 NIR dye-doped, 107
 photosensitizer, 109
 surface dependent optical properties, 109
 thermally-induced disproportionation, 109
 whole body imaging, 108
Silica nanoshells, 349
Silica protection layer, 569
Silicon dioxide, 147

- Silicon particles
 ball mill, 133
 infrared spectroscopy, 133, 135
 synthesis, 129, 133, 139, 141
- Silicon quantum dots (Si QDs), 109
- Single-cell, 237, 238
- Single-modality, 408
- Single-particle trapping, 224
- Single photon emission computed tomography (SPECT), 512–516, 525
 computed tomography imaging, 516–520
 diethylenetriaminepentaacetic acid, 513, 515
 indium-111, 512, 515
 magnetic resonance imaging, 520–521
 optical imaging, 521–523
 radionuclides, 512
 sentinel lymph node, for lymphatic system, 516
 specificity, 520, 522
 SPECT/CT imaging, 516–520
 SPECT/MR imaging, 520–521
 SPECT/optical imaging, 521–523
 technetium-99 m, 513, 514
- SiNPs, *see* Silica nanoparticles (SiNPs)
- Si QDs, *see* Silicon quantum dots (Si QDs)
- SLN, *see* Sentinel lymph node (SLN)
- Solid effect, 142
- Solid nanoparticles, 348–349
- Specific absorption rate, 149
- SPECT, *see* Single photon emission computed tomography (SPECT)
- Spectral acquisition
 mirror velocity, 174, 176
 number of co-additions, 174
 sampling aperture, 174
 spectral resolution, 174
- Spectral preprocessing, 174, 175
 classification system, 174
 de-noising, 174
 multivariate approaches, 175
 normalization, 174, 175
 spectral correction, 174
 validation, 174, 175
- Speed of sound (SOS), 339, 357
- Sperm, 296, 315
- Spin–lattice relaxation, 338, 349
- Spin–spin relaxation, 338, 350
- SPN-based NIR nanoprobe (NanoDRONE), 571
- SPR, *see* Surface plasmonic resonance (SPR)
- Sputum, 39, 41
- Squaraine dyes, 74
- Standard addition, 3
- Stem cells, 296, 304, 311, 312, 315
- Stokes Raman, 7, 9
- Subcutaneous tumor, 256
- Substrates, 169–171, 173, 174
 direct deposition, 173
- Superparamagnetism, 368
- Surface enhanced IR absorption (SEIRA), 175
- Surface-enhanced Raman spectroscopy (SERS), 220, 222, 223, 229, 233, 237, 239–241
 active substrates, 4, 6, 8, 10–12, 39, 42, 54
- Surface plasmonic resonance (SPR), 264, 427–429
- Surface plasmon polariton (SPP), 215–218, 220, 222, 223, 227, 231–233, 239–241
- Surface plasmon resonance imaging (SPRI), 220, 232, 233
- Surface plasmon resonance (SPR) sensors
 drug detection, 449–452
 hormone detection, 437–440
 in medical diagnosis, 429
 nucleic acid detection, 440–444
 optical sensors, 427
 principle of, 427–429
 protein detection, 429–437
 whole cell detection, 445–449
- Surface plasmons, 215, 218, 224
- Surface-related mechanism, 389
- Suzuki polymerization, 567
- Swine-influenza virus, 379
- T**
- T₁ values of nanoscale
 amine, 134, 135, 140, 141
 biodistribution, 140, 147
 spin polarization, 138
 undoped, 133, 137, 140, 144
- T₁-weighted images, 398
- T₂-weighted images, 397
- Target biomolecules, 371
- Target imaging, 81
- Targeting ligands, 512
- Tc, 369
- Technetium-99 m (^{99m}Tc), 512–514
- Telomerase, 50
- TEM, *see* Transmission electron microscopy (TEM)
- Testosterone, 438–439
- Theophylline, 450–451
- Theranostics, 523–527
- Therapeutic drug monitoring

- antibiotic administration, 45–46
 - anticancer drugs, 45
 - chromatographic separation, 44
 - illicit drugs, 49
 - immunological assays, 44–45
 - SERS, 46
 - standard addition method, 46–47
 - Thermal mixing, 142
 - Thermoplasmonic convection, 224, 228, 229, 240
 - Thiopurine S-methyltransferase
 - Thrombin, 52
 - Thrombin binding aptamer, 440
 - Tissues
 - bone, 313
 - bone marrow, 298
 - brain, 300, 301, 310
 - brain tumours, 199
 - breast, 297–299, 310
 - colon, 282, 297, 316
 - colorectal cancer, 200
 - connective tissues, 315
 - cornea, 300
 - endometrial tissue, 199
 - epithelial, 314
 - FFPE tissue, 169
 - fresh tissue, 200
 - hair, 280, 297, 305, 310, 311, 313, 315
 - liver, 300
 - lung tumour, 199
 - meibomian glands, 311
 - oral tissues, 199
 - ovarian tissue, 199
 - prostate, 199
 - salivary glands, 298
 - skin, 282, 284, 297, 298, 305, 312
 - snap-frozen tissue, 169
 - teeth, 280, 304
 - Top-down substrates, 10, 11
 - TPF microscopy, *see* Two-photon fluorescence (TPF) microscopy
 - Transforming growth factor, 3, 31
 - Transmission electron microscopy (TEM), 555
 - Triglyceride, 376
 - Tri-modal imaging
 - PEGylation, 262
 - X-ray computed tomography, 260
 - Troponin T (cTnT), 2, 20, 21
 - Tumor, 129, 149, 150, 153, 154
 - angiogenesis, 262
 - cells, 296
 - proliferative activity, 264
 - Tumor tracking, 564
 - persistent luminescence, 566
 - PIDT-DBT-Tat nanoparticles, 566
 - Tunable imaging parameters, 335
 - Two-photon absorption, 78
 - Two photon emission fluorescence, 315–317
 - Two-photon fluorescence (TPF) microscopy, 71–72
 - Two-photon *in vivo* imaging, 71
- U**
- UCL, *see* Up-conversion luminescence (UCL)
 - UCNCs, *see* Lanthanide-doped upconversion nanocrystals (UCNCs)
 - Ultrasonic imaging
 - acoustic impedance, 340
 - atherosclerosis, 347
 - attenuation coefficient, 339
 - biological approach, 346
 - carbon nanotubes, 349
 - Co₂, 348
 - computed tomography, 341
 - contrast-enhancing mechanism, 343
 - cross-section, 341
 - echogenic liposomes, 347–348
 - gas core nanobubbles, 344–346
 - gas-generating nanoparticles, 348
 - gas-generating nano-scaled substances, 344
 - H₂O₂, 348
 - nanodroplets, 346–347
 - projections, 341
 - pulse-echo, 341
 - reflected echoes, 340
 - scanning system, 341
 - solid nanoparticles, 348–349
 - speed of sound, 339
 - transmission coefficient, 340
 - transmission imaging, 341
 - vaporization, 347
 - Ultrasonic waves, 258
 - Ultrasound imaging, *see* Ultrasonic imaging
 - Ultrasound-induced magnetic imaging, 411–419
 - Ultraviolet-vis spectrometer, 547
 - Unspecific uptake in liver, polymer dots, 573
 - Up-conversion luminescence (UCL), 71
 - Upconversion nanoparticles
 - antigen-antibody interactions, 103
 - biofunctionality, 102
 - hydrophobic-hydrophobic interaction, 101
 - NIR-to-NIR upconversion photoluminescence, 101

- Upconversion nanoparticles (*cont.*)
 photo-bleaching, 101
 target-specific recognition, 103
 upconversion excitation efficiency, 103
 water-soluble system, 101
- UV absorption and fluorescence spectra
 bioluminescence emission spectra, 547
 dual-modal fluorescence, 548
 fluorometer, 549
 photo-luminescence spectra, 549
 spectrofluorometer, 548
 spectrophotometer, 548
- V**
- Vancomycin, 3
Vascular endothelial growth factor, 376
Vertex component analysis, 294, 312
Vertical-flow paper, 48
Vibrating sample magnetometer, 380–384
Vibrational spectroscopy, 5
- Viruses, 214, 227, 238
Vitamins, detection of, 296, 300, 302, 308, 315
- W**
- Whole cell detection
 adenovirus, 445
 avian influenza virus detection, 445
 bacteriophage MS2, 445
 canine distemper virus, 445
 Escherichia coli, 447–448
 mesenchymal stem cells, 449
 Salmonella, 448
- X**
- Xanthenes dyes, 76
- Y**
- Yeast, 295